B2M and melanoma: Researchers found that mutations in beta-2-microglobulin (B2M) and Janus kinase1/2 (JAK1/2) genes are associated with a decreased response to pembrolizumab treatment by suppressing antigen presentation and interferon signaling in melanoma patients regardless of the high TMB, suggesting that a more specific mutational signature is needed to predict patients’ response to ICI in addition to the TMB16.